Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA

Amit G. Singal, Saurabh P. Nagar, Abby Hitchens, Keith L. Davis, Shrividya Iyer

Research output: Contribution to journalArticlepeer-review

Abstract

Aim: This study evaluated the effectiveness of lenvatinib monotherapy for first-line treatment of unresectable hepatocellular carcinoma (uHCC) in a real-world setting. Materials & methods: This retrospective cohort study included patients who initiated lenvatinib monotherapy as first-line treatment for uHCC (n = 233). Clinical outcomes included provider-reported best response, progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using Kaplan-Meier methods. Results: Most patients (67.8%) were male. A total of 44.6% had Child-Pugh A and 39.1% had Child-Pugh B. Dose reductions were reported in 9%. Median PFS and OS were not reached. At 6 and 12 months, landmark PFS were 85.1 and 64.9%, respectively; landmark OS were 91.8 and 72.6%, respectively. Conclusion: These results affirm the clinical effectiveness of first-line lenvatinib monotherapy in uHCC.

Original languageEnglish (US)
Pages (from-to)2759-2768
Number of pages10
JournalFuture Oncology
Volume17
Issue number21
DOIs
StatePublished - Jul 2021

Keywords

  • chart review
  • hepatocellular carcinoma
  • lenvatinib
  • real-world data
  • survival analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients in the USA'. Together they form a unique fingerprint.

Cite this